ABSK PRMT5 1
Alternative Names: ABK-PRMT5-1; ABSK-PRMT5-1Latest Information Update: 19 Oct 2023
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Oct 2023 ABSK PRMT5 1 is available for licensing as of 16 Oct 2023. https://www.abbisko.com/Partnership.html (Abbisko Therapeutics pipeline, October 2023)
- 16 Oct 2023 Preclinical trials in Cancer in China (PO)
- 16 Oct 2023 Pharmacodynamics and pharmacokinetics data from preclinical trials in Cancer presented at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-2023)